HomeAI · summaries
Storia in 3 fonti
Tyra disappoints investors with bladder cancer data
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Tyra disappoints investors with bladder cancer data
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
- ·
endpoints.news
Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data
Tyra Biosciences released Phase 2 data for dabogratinib, targeting bladder cancer, aiming to rival J&J's Balversa, with a 60mg dose showing 57% complete response rate.
